Amgen touts new Aranesp studies

Could this be evidence to help tip Medicare scales toward an about-face on anemia drugs? Amgen is touting two new studies: one that showed extended doses of its Aranesp anemia drug every two to three weeks with chemotherapy was safe, and as effective at raising hemoglobin levels as more frequent treatment is. The second? A meta-analysis of six trials, which seems to indicate that Aranesp treatment decreases blood transfusions and "other events."

Yesterday, you know, Medicare said it needed hard evidence that the drugs work better than drug transfusions to alleviate anemia. Otherwise, its July decision to cut reimbursements for the drugs--which include Aranesp, plus Amgen's Epogen and Johnson & Johnson's Procrit--will stand.

- check out the press release from Amgen

Related Articles:
Medicare upholds anemia drug cuts. Report
At corporate HQ, Amgen drops the axe. Report
Amgen wins a round in anemia ruckus. Report
Amgen discusses the future with analysts. Report
New rules limit use of anemia drugs. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.